$60.74
1.37% today
Nasdaq, Nov 26, 04:49 pm CET
ISIN
US76243J1051
Symbol
RYTM
Sector
Industry

Rhythm Pharmaceuticals, Inc. Target price 2024 - Analyst rating & recommendation

Rhythm Pharmaceuticals, Inc. Classifications & Recommendation:

Buy
91%
Hold
9%

Rhythm Pharmaceuticals, Inc. Price Target

Target Price $70.27
Price $59.92
Potential
Number of Estimates 11
11 Analysts have issued a price target Rhythm Pharmaceuticals, Inc. 2025 . The average Rhythm Pharmaceuticals, Inc. target price is $70.27. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 11 analysts: 10 Analysts recommend Rhythm Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Rhythm Pharmaceuticals, Inc. stock has an average upside potential 2025 of . Most analysts recommend the Rhythm Pharmaceuticals, Inc. stock at Purchase.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Revenue Million $ 77.43 124.46
227.54% 60.73%
EBITDA Margin -235.83% -213.01%
68.64% 9.67%
Net Margin -253.92% -210.14%
71.93% 17.24%

11 Analysts have issued a sales forecast Rhythm Pharmaceuticals, Inc. 2024 . The average Rhythm Pharmaceuticals, Inc. sales estimate is

$124m
Unlock
. This is
10.60% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$127m 12.77%
Unlock
, the lowest is
$123m 9.48%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 $77.4m 227.54%
2024
$124m 60.73%
Unlock
2025
$178m 43.24%
Unlock
2026
$312m 75.18%
Unlock
2027
$626m 100.41%
Unlock
2028
$933m 49.06%
Unlock

3 Analysts have issued an Rhythm Pharmaceuticals, Inc. EBITDA forecast 2024. The average Rhythm Pharmaceuticals, Inc. EBITDA estimate is

$-265m
Unlock
. This is
0.45% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$-254m 3.58%
Unlock
, the lowest is
$-273m 3.41%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 $-183m 2.73%
2024
$-265m 45.18%
Unlock
2025
$-174m 34.40%
Unlock
2026
$-125m 28.00%
Unlock

EBITDA Margin

2023 -235.83% 68.64%
2024
-213.01% 9.67%
Unlock
2025
-97.55% 54.20%
Unlock
2026
-40.10% 58.89%
Unlock

3 Rhythm Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2024. The average Rhythm Pharmaceuticals, Inc. net profit estimate is

$-262m
Unlock
. This is
1.92% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-247m 7.37%
Unlock
, the lowest is
$-273m 2.54%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 $-197m 8.05%
2024
$-262m 33.02%
Unlock
2025
$-146m 44.09%
Unlock
2026
$-4.6m 96.85%
Unlock
2027
$169m 3,765.08%
Unlock
2028
$378m 123.64%
Unlock

Net Margin

2023 -253.92% 71.93%
2024
-210.14% 17.24%
Unlock
2025
-82.03% 60.96%
Unlock
2026
-1.48% 98.20%
Unlock
2027
27.00% 1,924.32%
Unlock
2028
40.50% 50.00%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '23 2024
Estimates
Earnings Per Share $ -3.20 -4.26
8.05% 33.13%
P/E negative
EV/Sales 29.24

3 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast for earnings per share. The average Rhythm Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-4.26
Unlock
. This is
1.84% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-4.02 7.37%
Unlock
, the lowest is
$-4.45 2.53%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 $-3.20 8.05%
2024
$-4.26 33.13%
Unlock
2025
$-2.38 44.13%
Unlock
2026
$-0.08 96.64%
Unlock
2027
$2.75 3,537.50%
Unlock
2028
$6.15 123.64%
Unlock

P/E ratio

Current -13.81 29.92%
2024
-14.08 1.96%
Unlock
2025
-25.18 78.84%
Unlock
2026
-798.93 3,072.88%
Unlock
2027
21.79 102.73%
Unlock
2028
9.74 55.30%
Unlock

Based on analysts' sales estimates for 2024, the Rhythm Pharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

29.24
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
29.59
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 32.34 8.12%
2024
29.24 9.59%
Unlock
2025
20.41 30.19%
Unlock
2026
11.65 42.92%
Unlock
2027
5.81 50.10%
Unlock
2028
3.90 32.91%
Unlock

P/S ratio

Current 32.72 0.92%
2024
29.59 9.58%
Unlock
2025
20.66 30.19%
Unlock
2026
11.79 42.92%
Unlock
2027
5.88 50.10%
Unlock
2028
3.95 32.91%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today